Ocular Therapeutix™ Announces Pricing of Public Offering of Common Stock
October 14, 2020
Ocular Therapeutix™ Announces Proposed Public Offering of Common Stock
October 13, 2020
Ocular Therapeutix™ Announces Topline Phase 1 Clinical Trial Results of OTX-CSI
October 08, 2020
Ocular Therapeutix Announces Preliminary Net Product Revenue of $5.8 Million to $5.9 Million for Third Quarter 2020, Representing Greater Than a 250% Increase Over the Previous Quarter
October 07, 2020
Ocular Therapeutix Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
October 06, 2020
Ocular Therapeutix™ Announces First Patients Dosed in Phase 2 Clinical Trial of OTX-CSI for the Treatment of Dry Eye Disease
September 29, 2020
Ocular Therapeutix™ Announces First Patient Dosed in Phase 3 Clinical Trial of DEXTENZA® for the Treatment of Post-Surgical Ocular Inflammation and Pain in Children
September 10, 2020
Ocular Therapeutix™ Announces Successful Resolution of FDA Warning Letter Related to ReSure® Sealant
September 08, 2020
Ocular Therapeutix Announces Third Medicare Administrative Contractor to Establish New Published Physician Fee Schedule for Administration of Intracanalicular Inserts
September 04, 2020
Ocular Therapeutix™ to Present at Two Upcoming Investor Conferences
September 03, 2020
Ocular Therapeutix™ Reports Second Quarter 2020 Financial Results and Business Update
August 07, 2020
Ocular Therapeutix™ To Report Second Quarter 2020 Financial Results
July 31, 2020
Ocular Therapeutix Announces Second Medicare Administrative Contractor to Establish New Published Physician Fee Schedule for Administration of Intracanalicular Inserts
July 23, 2020
Ocular Therapeutix Presents at the 12th Annual Ophthalmology Innovation Summit (OIS)
July 17, 2020
Ocular Therapeutix Announces Its First Published Physician Fee Schedule for Administration of Intracanalicular Inserts
July 15, 2020
Ocular Therapeutix™ to Hold Virtual 2020 Annual Meeting Of Stockholders
June 15, 2020
Ocular Therapeutix™ to Present Data at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
June 15, 2020
Ocular Therapeutix™ to Present at the 2020 Raymond James Human Health Innovation Conference
June 10, 2020
Ocular Therapeutix™ to Present at the Jefferies Virtual Healthcare Conference
May 29, 2020
Ocular Therapeutix™ Announces Pricing of Public Offering of Common Stock
May 20, 2020
Ocular Therapeutix™ Announces Proposed Public Offering of Common Stock
May 19, 2020
Ocular Therapeutix™ Announces First Patient Dosed in Phase 1 Clinical Trial of OTX-CSI for the Treatment of Dry Eye Disease
May 12, 2020
Ocular Therapeutix™ To Present New Data at the American Society of Cataract and Refractive Surgery (ASCRS) 2020 Virtual Annual Meeting
May 11, 2020
Ocular Therapeutix™ Reports First Quarter 2020 Financial Results and Business Update
May 08, 2020
Ocular Therapeutix™ To Report First Quarter 2020 Financial Results
April 30, 2020
Ocular Therapeutix™ Announces Topline Results of Phase 3 Clinical Trial of DEXTENZA® for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis
April 28, 2020
Ocular Therapeutix™ Provides Business Update and Response to COVID-19 Global Pandemic
April 13, 2020
Ocular Therapeutix™ Reports Fourth Quarter and Year End 2019 Financial Results and Business Update
March 12, 2020
Ocular Therapeutix™ To Report Fourth Quarter and Year-End 2019 Financial Results
March 05, 2020
Ocular Therapeutix™ Announces Preliminary Fourth Quarter 2019 Net Product Revenue and Provides Update on Interim Data from the OTX-TKI Phase 1 Clinical Trial at the Cowen 40th Annual Health Care Conference
March 03, 2020
Ocular Therapeutix™ to Present at the Cowen and Company 40th Annual Health Care Conference
February 25, 2020
Ocular Therapeutix™ Presents Data Demonstrating a Clinically-Meaningful Reduction in Intraocular Pressure in Patients with Primary Open Angle Glaucoma or Ocular Hypertension Treated with OTX-TIC at Glaucoma 360 Conference
February 07, 2020
